Edition:
India

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

8.83EUR
23 May 2018
Change (% chg)

€-0.09 (-1.06%)
Prev Close
€8.93
Open
€8.93
Day's High
€8.93
Day's Low
€8.79
Volume
29,625
Avg. Vol
103,906
52-wk High
€13.68
52-wk Low
€7.65

Latest Key Developments (Source: Significant Developments)

Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer
Friday, 20 Apr 2018 

April 20 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER.SELLAS LIFE SCIENCES GROUP INC - INTERIM CHIEF FINANCIAL OFFICER ALEKSEY KRYLOV WILL REMAIN WITH SELLAS UNTIL JULY 15.SELLAS LIFE SCIENCES GROUP INC - MACK MOST RECENTLY SERVED AS A CONSULTING CFO, MOST RECENTLY WITH NICOX, SA.  Full Article

Nicox Updates on Drug Development And Outlines 2018 Activities
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - NICOX SA ::RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT.ESTIMATES THAT THE U.S. PATENTS COVERING VYZULTA COULD BE EXTENDED FROM 2025 TO 2030..EXPECTS TO BEGIN RECEIVING ROYALTY REVENUE IN 2018, ALONG WITH POTENTIAL SALES AND DEVELOPMENT MILESTONES PAYMENTS‍​.NCX 470 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.NCX 4251 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.  Full Article

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article

Nicox says ‍cash balance was 47.1 million euros as of Sept. 30
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - NICOX SA ::‍CASH BALANCE OF EUR 47.1 MILLION AS OF SEPTEMBER 30, 2017​.Q3 NO REVENUE ‍​ VERSUS NO REVENUE YEAR AGO.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Nicox and pSivida enter strategic collaboration agreement
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - NICOX SA ::REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA.NEW INTELLECTUAL PROPERTY FROM THE COLLABORATION RELATING TO THE DRUG-DEVICE COMBINATION WILL BE JOINTLY OWNED‍​.PSIVIDA TO BE RESPONSIBLE FOR INITIAL DEVELOPMENT ACTIVITIES OF OCULAR INSERT FORMULATIONS, FOR WHICH IT WILL RECEIVE UNDISCLOSED SUMS BY NICOX‍​.  Full Article

Nicox receives complete response letter from FDA for AC-170
Monday, 10 Oct 2016 

Nicox SA : Receives complete response letter from FDA related to GMP on NDA for AC-170 . FDA's stated reason for CRL pertains to good manufacturing practice inspection at a third party facility producing API cetirizine and supplying it to manufacturer of finished product .Safety and efficacy data submitted by Nicox in AC-170 NDA have not resulted in FDA requesting any further clinical or non-clinical testing for approval.  Full Article

Nicox raises 18 mln euros to finance R&D
Thursday, 28 Jul 2016 

Nicox SA : Nicoxraises 18 million euros ($20.0 million) to finance development of its pipeline .Proceeds to finance development of NCX 4251 in blepharitis and NCX 470 in glaucoma and for general corporate purposes.  Full Article

FDA to inspect Nicox partner Bausch + Lomb
Friday, 22 Jul 2016 

Nicox SA : Has been informed by its partner Bausch + Lomb, a Valeant unit , of receipt of a complete response letter from U.S. FDA concerning latanoprostene bunod . FDA's letter did not identify any efficacy or safety concerns with respect to NDA or additional clinical trials needed for approval of NDA for latanoprostene bunod ophthalmic solution, 0.024 pct . Concerns raised by the FDA pertain to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb's manufacturing facility in Tampa, Florida . Some deficiencies were identified by the FDA at the Tampa plant .Valeant intends to meet with FDA as soon as possible to work on a resolution and address these concerns.  Full Article

Nicox to transfer commercial operations to new company, gets minority stake
Tuesday, 5 Jul 2016 

Nicox SA : Nicox to transfer commercial operations to new pan-European ophthalmic specialty pharmaceutical company led by GHO Capital . Transaction values Nicox's European and international commercial operations and related late-stage development programs at up to 26 million euros ($28.9 million) .Nicox to receive a 9 million euro upfront cash payment and a minority stake in new company.  Full Article

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017